Table 4 The course for clinical parameters in studied groups

HbA1C1

6.83 ± 1.24

7.98 ± 1.17

8.49 ± 1.26

9.67 ± 1.64

HbA1C3

6.77 ± 0.8

7.73 ± 1.17

7.76 ± 0.93

8.85 ± 1.72

Reduction in HbA1C

−0.06 ± 1.04

−0.25 ± 0.72

−0.73 ± 1.27

−0.82 ± 0.78

P value within group

P = 0.97

P = 0.39

P = 0.023

P = 0.11

OxLDLc1

1272.5 ± 395.35

1558.3 ± 552.74

1590.3 ± 586.57

1518.4 ± 292.61

OxLDLc3

1135.4 ± 427.51

1063.8 ± 513.64

1277.3 ± 590.41

1263.4 ± 1064.56

Reduction in oxLDLc

−137.1 ± 517.52

−494.5 ± 625.1

−312.9 ± 514.55

−255 ± 931.2

−131(−1744–870)

−513.5(−2066–1255)

−391(−1100–833)

−639(−1379–1585)

P value within group

P = 0.044

P = 0.002

P = 0.017

P = 0.002

OxLDL/LDLc1

11.47 ± 3.02

15.28 ± 7.43

14.76 ± 5.95

15.09 ± 4.92

OxLDLc/LDLc3

10.26 ± 3.83

10.16±5.47

11.86 ± 5.55

13.48 ± 12.95

Reduction in oxLDLc/LDLc

−1.2 ± 4.08

−5.12 ± 5.03

−2.89 ± 4.53

−1.62 ± 9.92

−1.38(−10.38–7.7)

−5.5(−13.11–7.22)

−2.34(−11.96–5.37)

−4.96(−11.83–19.33)

P value within group

P = 0.15

P = 0.009

P = 0.07

P = 0.018

OxLDL/HDLc1

31.38 ± 11.61

37.49 ± 13.69

39.81 ± 15.42

44.13 ± 11.99

OxLDL/HDLc3

29.17 ± 16.86

26.32 ± 14.49

32.12 ± 15.91

37.86 ± 36.36

Reduction in oxLDLc/HDLc

−2.21 ± 12.76

−11.18 ± 15.93

−7.68 ± 12.84

−6.28 ± 29.43

−2.98(−32.3–30)

−12.88(−54.39–35.88)

−7.82(−25–22.51)

−15.98(−47.55–52.83)

P value within group

P = 0.11

P = 0.001

P = 0.05

P = 0.002

MDA1

9.62 ± 2.56

8.05 ± 2.63

10.38 ± 2.65

9.6 ± 3.68

MDA3

8.41 ± 2.55

8.04 ± 2.72

7.34 ± 1.87

8.7 ± 2.58

Reduction in MDA

−1.2 ± 3.34 

−0.01 ± 3.37

−3.03 ± 2.95

−0.9 ± 3.55

−1.2(−7–7)

−1.5 (−8–6)

−2(−9–0.8)

−0.5(−8–4)

P value within group

P = 0.1

P = 0.93

P = 0.0001

P = 0.31